A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2783-y
Published Online: 2015-06-12
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Makielski, Rory J.
Lubner, Sam J.
Mulkerin, Daniel L.
Traynor, Anne M.
Groteluschen, David
Eickhoff, Jens
LoConte, Noelle K.
Text and Data Mining valid from 2015-06-12